Positive Clinical Results and New Launches Might Change the Case For Investing In Teva (TEVA)

• Teva Pharmaceuticals recently presented positive long-term safety data for its once-monthly olanzapine long-acting injectable and highlighted strong patient satisfaction with AUSTEDO XR at the 2025 Psych Congress Annual Meeting, alongside the US launch of the first generic GLP-1 weight loss drug and UZEDY’s regulatory approval in South Korea by Teva Handok.
• These developments reflect Teva's momentum in neuropsychiatry and weight-management markets, with product launches and clinical results enhancing anticipation for future growth and innovation.
• We'll explore how encouraging clinical outcomes for Teva’s olanzapine LAI could influence the company's future earnings profile and projected growth.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Teva Pharmaceutical Industries Investment Narrative Recap

To be a Teva shareholder is to believe in the company’s ability to convert recent clinical wins and pipeline progress in neuropsychiatry into sustainable, higher-margin growth, while working through persistent challenges from generics, pricing pressures, and a sizeable debt load. The latest positive safety data for olanzapine LAI and strong UZEDY sales affirm Teva's momentum in branded drugs, but the impact on the company’s biggest short-term catalyst, greater earnings visibility from innovation, will depend on successful further launches and expansion. The risk from concentrated reliance on a handful of innovative products remains material, especially considering the potential impact of future price negotiations on margins.

Relevant here is the newly announced regulatory approval and strong US sales trajectory for UZEDY, Teva's long-acting injectable for schizophrenia. As revenue from UZEDY climbs and further international approvals emerge, management's case for pivoting toward specialty and innovative medicines as primary growth drivers comes into sharper focus alongside the short-term catalyst of sustained branded product launch momentum.

However, with continued dependence on AUSTEDO, AJOVY, and UZEDY for growth, investors should be aware that...

Read the full narrative on Teva Pharmaceutical Industries (it's free!)

Teva Pharmaceutical Industries' outlook anticipates $17.8 billion in revenue and $1.5 billion in earnings by 2028. This reflects a 2.3% annual revenue growth and an increase in earnings of $1.66 billion from the current earnings of -$157 million.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $23.56 fair value, a 25% upside to its current price.

Exploring Other Perspectives

The Simply Wall St Community’s 14 fair value estimates for Teva range from US$23.56 to US$57.80, highlighting wide differences in investor opinion. While many expect value recovery from innovation-backed growth, concentrated risk in a few key products could shape future performance, read different community perspectives to see how others weigh these factors.

Explore 14 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth just $23.56!

Build Your Own Teva Pharmaceutical Industries Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

No Opportunity In Teva Pharmaceutical Industries?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com